MeRT (Magnetic e-Resonance Therapy) is not FDA approved as a standalone treatment. It is a proprietary protocol built on top of transcranial magnetic stimulation (TMS) hardware that is FDA cleared, but the MeRT protocol itself, which customizes how that hardware is used, has not received its own FDA approval or clearance for any condition. In 2024, Wave Neuroscience, the company behind MeRT, did receive FDA breakthrough device designation for MeRT as an adjunctive treatment for PTSD, but that designation is not the same as approval.
What MeRT Actually Is
MeRT is a personalized form of TMS guided by two additional data sources: a quantitative EEG (qEEG) that maps your brainwave patterns and an electrocardiogram (EKG) that records your heart rhythm. Clinicians use this combined brain and heart data to customize the stimulation frequency, intensity, and location for each patient, rather than relying on the standardized settings used in traditional TMS.
Standard repetitive TMS (rTMS) protocols typically stimulate a fixed brain region called the dorsolateral prefrontal cortex at a set frequency, commonly 10 Hz or a burst pattern at 50 Hz. MeRT instead targets different EEG electrode positions and matches the stimulation frequency to your individual alpha brainwave rhythm, which falls in the 9 to 12 Hz range. Sessions run about 29 to 30 minutes, compared to as little as 3 minutes for some standard TMS protocols.
Breakthrough Designation vs. FDA Approval
The distinction matters. FDA breakthrough device designation is a pathway designed to speed up the development and review of devices that may offer significant advantages over existing treatments for serious conditions. It gives the company more direct access to FDA guidance and a potentially faster review process. It does not mean the device or protocol has been evaluated for safety and effectiveness, and it does not authorize marketing the treatment as FDA approved.
Wave Neuroscience received this designation specifically for MeRT as an adjunctive (add-on) treatment for PTSD. The company is currently running a clinical trial in partnership with Texas A&M examining MeRT in 175 patients with PTSD, with or without persistent post-concussion symptoms from traumatic brain injury. That trial involves five weeks of daily sessions, with participants receiving either active or simulated (placebo) MeRT. Until trials like this produce results and the FDA reviews them, MeRT remains investigational.
Why Some Clinics Say “FDA Approved”
Some MeRT providers describe the treatment as FDA approved or FDA cleared, which is misleading. What is FDA cleared is the TMS machine itself, the hardware that delivers magnetic pulses to the brain. TMS devices have been cleared for treatment-resistant depression since 2008 and for several other conditions since then. MeRT uses this same cleared hardware but applies it in a different way, with different targeting and individualized frequencies, that has not been separately evaluated by the FDA.
Think of it like this: a scalpel is an FDA-cleared medical device, but a new surgical technique performed with that scalpel would need its own clinical evidence before it could be called proven. MeRT is the new technique; the TMS machine is the scalpel.
What the Research Shows So Far
The evidence base for MeRT is still thin. For depression, a retrospective chart review has compared MeRT to standard rTMS protocols, but retrospective reviews are a low tier of evidence because they look backward at patient records rather than testing treatments in controlled conditions. For PTSD, the ongoing Texas A&M trial is in its second phase with a larger and more diverse patient group, but results have not yet been published.
For autism spectrum disorder, the picture is even less clear. The Association for Science in Autism Treatment has noted that no large-scale studies have demonstrated significant differences between MeRT and placebo for autism symptoms, and Wave Neuroscience has not published or disclosed clinical trial results related to MeRT and autism. Despite this, some clinics actively market MeRT for autism. At least one FDA adverse event report documents a five-year-old who experienced worsening symptoms during MeRT treatment for autism, including loss of speech, disrupted sleep, and episodes of severe pain.
Cost and Insurance Coverage
A full course of MeRT typically costs between $2,000 and $10,000, covering initial assessments and multiple sessions over several weeks. Because MeRT itself lacks FDA approval, most insurance plans do not cover it. Some providers accept Tricare Prime and Select, the military health insurance plans, which makes sense given the focus on PTSD and TBI in veteran populations. If you are considering MeRT, check with your insurance provider directly, but expect to pay out of pocket.
What This Means for You
If you are exploring MeRT, the key facts are straightforward. The TMS hardware used in MeRT is FDA cleared. The MeRT protocol layered on top of that hardware is not FDA approved or cleared for any condition. It has breakthrough device designation for PTSD, which accelerates the review process but is not an endorsement of effectiveness. Clinical trials are underway but have not yet produced published results that would support approval.
Any clinic telling you MeRT is “FDA approved” is either confused about the distinction between the device and the protocol or is overstating the evidence. That does not necessarily mean the treatment cannot help, but it does mean the level of proof is not yet where standard medical treatments are, and the financial risk falls entirely on you.